Recombinant antibody fragments

Current Opinion in Biotechnology

Volumn 9, Issue 4, 1998, Pages 395-402

  Hudson, Peter J ^a  

^a CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CATALYTIC ANTIBODY; DRUG; ENZYME; RADIOISOTOPE; RECOMBINANT PROTEIN; TOXIN;

ANTIBODY STRUCTURE; BIOSENSOR; CANCER IMMUNOTHERAPY; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0032146225     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(98)80014-1     Document Type: Article

References (67)

1. Carter P, Merchant AM. Engineering antibodies for imaging and therapy. Curr Opin Biotechnol. 8:1997;449-454.
2. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:1997;2188-2195.
3. Parren PW, Burton DR. Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy. Chem Immunol. 65:1997;18-56.
4. Dall'Acqua W, Carter P. Antibody engineering. Curr Opin Struct Biol. 1998.
5. Banfield MJ, King DJ, Mountain A, Brady RL. V-domain rotations in engineered antibodies-crystal structures of the Fab fragments from two murine antitumour antibodies and their engineered human constructs. Proteins - Struct Func Genet. 29:1997;161-171.
6. Hoogenboom HR, De Bruine AP, Hufton SE, Hoet RM, Rends J-W, Roovers RC. Antibody Phage Display technology and its applications. Immunotechnology. 1998.
7. Rader C, Barbas CF III. Phage display of combinatorial antibody libraries. Curr Opin Biotechnol. 8:1997;503-508.
8. Baca M, Presta LG, O'Connor SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem. 272:1997;10678-10684.
9. Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnol. 3:1997;83-105.
10. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58:1998;485-490.
11. Dougan DA, Malby RL, Gruen LC, Kortt AA, Hudson PJ. Effects of substitutions in an antibody binding surface on antigen affinity. Protein Eng. 11:1998;65-74.
12. H or single chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molcules. Proc Natl Acad Sci USA. 94:1997;9261-9266.
13. Kortt AA, Lah M, Oddie GW, Gruen LC, Burns JE, Pearce LA, Atwell JA, McCoy AJ, Howlett GJ, Metzger DW, et al. Single chain Fv Fragments of anti-neuraminidase antibody NC10 containing five and ten residue linkers form dimers and with zero residue linker a trimer. Protein Eng. 10:1997;423-433.
14. Turner DJ, Ritter MA, George AJT. Importance of the linker in expression of single-chain Fv antibody fragments - optimisation of peptide sequences using phage display technology. J Immunol Methods. 205:1997;43-54.
15. De Wildt RM, Ruytenbeek R, van Venrooij WJ, Hoet RM. Heavy chain CDR3 optimization of a germline encoded recombinant antibody fragment predisposed to bind the U1A protein. Protein Eng. 10:1997;835-841.
16. Komissarov AA, Marchbank MT, Calcutt MU, Quinn TP, Deutscher SL. Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction. J Biol Chem. 272:1997;26864-26870.
17. Barbas CF III, Heine A, Zhong G, Hoffmann T, Gramatikova S, Bjornestedt R, Anderson J, Stura EA, Wilson IA, Lerner RA. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science. 278:1997;2085-2092.
18. McCoy AJ, Epa VC, Colman PM. Electrostatic complementarity at protein/protein interfaces. J Mol Biol. 268:1997;570-584.
19. Arbabi Ghahroudi M, Desmyler A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414:1997;521-526.
20. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science. 276:1997;1665-1669.
21. Colman PM. Structure of antibody-antigen complexes: implications for immune recognition. Adv Immunol. 43:1988;99-132.
22. Kipriyanov SM, Moldenhauer G, Martin ACR, Kupriyanova OA, Little M. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10:1997;445-453.
23. Nieba L, Honegger A, Krebber C, Plückthun A. Distrupting the hydrophobic patches at the antibody variable/constant domain interface - improved in vivo folding and physical characterisation of an engineered scFv fragment. Protein Eng. 10:1997;435-444.
24. Forsberg G, Forsgren M, Jaki M, Norin M, Sterky C, Enhorning A, Larsson K, Ericsson M, Bjork P. Identification of framework residues in a secreted recombinant antibody fragment that control production level and localisation in E. coli. J Biol Chem. 272:1997;12430-12436.
25. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 270:1997;26-35.
26. L permutation. J Mol Biol. 268:1997;107-117.
27. Fitzgerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilised diabodies expressed in Pichia pastoris. Protein Eng. 10:1997;1221-1225.
28. Tsumoto K, Nishimiya Y, Kasai N, Ueda H, Nagamune T, Ogasahara K, Yutani K, Tokushisa K, Matsushima M, Kumagai I. Novel selection method for engineered antibodies using the mechanism of Fv fragment stabilization in the presence of antigen. Protein Eng. 10:1997;1311-1318.
29. Uson I, Bes MT, Sheldrick GM, Schneider TR, Hartsch T, Fritz H-J. X-ray crystallography reveals stringent conservation of protein fold after removal of the only disulfide bridge from a stabilised immunoglobulin variable domain. Fold Des. 2:1997;357-362.
30. Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Ann Rev Microbiol. 51:1997;257-283.
31. Gargano N, Cattaneo A. Inhibition of murine leukaemia virus retrotranscription by the intracellular expression of a phage-derived anti-reverse transcriptase antibody fragment. J Gen Virol. 78:1997;2591-2599.
32. Roux KH, Strelets L, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 159:1997;3372-3382.
33. Thouvenin E, Laurent S, Madelaine MF, Rasschaert D, Vautherot JF, Hewat EA. Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. J Mol Biol. 270:1997;238-246.
34. Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA. 94:1997;7509-7514.
35. Iliades P, Kortt AA, Hudson PJ. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409:1997;437-441.
36. H CDR3. Proc Natl Acad Sci USA. 94:1997;9637-9642.
37. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Brit J Cancer. 77:1998;1405-1412.
38. Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Brit J Cancer. 74:1996;1397-1405.
39. Lawrence LJ, Kortt AA, Iliades P, Tulloch PA, Hudson PJ. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments. FEBS Lett. 425:1998;479-484.
40. Kontermann RE, Martineau P, Cummings CE, Karpas A, Allen D, Derbyshire E, Winter G. Enzyme immunoassays using bispecific diabodies. Immunotechnol. 3:1997;137-144.
41. Libyh MT, Gossens D, Oudin S, Gupta N, Dervillez X, Juszczak G, Cornillet P, Bougy F, Reveil B, Philbert F, et al. A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein. Blood. 90:1997;3978-3983.
42. Li E, Pedraza A, Bestagno M, Mancardi S, Sanchez R, Burrone O. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng. 10:1997;731-736.
43. Holliger P, Wing M, Pound JD, Bohlen H, Winter G. Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol. 15:1997;632-636.
44. Kontermann RE, Wing MG, Winter G. Complement recruitment using bispecific diabodies. Nat Biotechnol. 15:1997;629-631.
45. Kufer P, Mack M, Gruber R, Lutterbuse R, Zettl F, Riethmuller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol. 45:1997;193-197.
46. Brekke OH, Michaelsen TE, Sandlin R, Sandlie I. Activation of complement by an IgG molecule without a genetic hinge. Nature. 383:1996;103.
47. Coloma MJ, Trinh KR, Wims LA, Morrison SL. The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol. 158:1997;733-740.
48. Ghetie MA, Ghetie V, Vitetta ES. Immunotoxins for the treatment of B-cell lymphomas. Mol Med. 3:1997;420-427.
49. Zewe M, Rybak SM, Dubel S, Coy JF, Welschof M, Newton DL, Little M. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnol. 3:1997;127-136.
50. Pastan I. Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta. 1333:1997;C1-C6.
51. Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol. 40:1997;189-201.
52. Siemers NO, Kerr DE, Yarnold S, Stebbins MR, Vrudhula VM, Hellstrom I, Hellstrom KE, Senter PD. Construction, expression and activities of a single-chain antibody-beta-lactamase fusion protein for anticancer prodrug activation. Bioconjug Chem. 8:1997;510-519.
53. Penichet ML, Harvill ET, Morrison SL. Antibody-IL-2 fusion proteins: a novel strategy for immune protection. Hum Antibodies. 8:1997;106-118.
54. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 45:1997;131-136.
55. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, Kovesdi I, Segal DM. Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 71:1997;7663-7669.
56. Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE. The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4:1997;1004-1012.
57. Chu THT, Dornburg R. Toward highly efficient cell-type specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol. 71:1997;720-725.
58. Kobatake E, Sasakura H, Haruyama T, Laukkanen ML, Keinanen K, Aizawa MA. Fluoroimmunoassay based on immunoliposomes containing genetically engineered lipid-tagged antibody. Anal Chem. 69:1997;1295-1298.
59. Kerschbaumer RJ, Hirschl S, Kaufmann A, Ibl M, Koenig R, Himmler G. Single chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked immunosorbent assay. Anal Biochem. 249:1997;219-227.
60. Hanes J, Plückthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA. 94:1997;4937-4942.
61. Coia G, Ayres A, Lilley GG, Hudson PJ, Irving RA. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene. 201:1997;203-209.
62. Zhao H, Giver L, Shao Z, Affholter JA, Arnold FH. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol. 16:1998;258-261.
63. Mahler SM, Marquis CP, Brown G, Roberts A, Hoogenboom HR. Cloning and expression of human V-genes derived from phage display libraries as fully assembled human anti-TNF alpha monoclonal antibodies. Immunotechnology. 3:1997;31-43.
64. Malmborg AC, Soderlind E, Frost L, Borrebaeck CA. Selective phage infection mediated by epitope expression on F pilus. J Mol Biol. 273:1997;544-551.
65. Pedrazzi G, Schweisinger F, Honegger A, Krebber C, Plückthun A. Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology. FEBS Lett. 415:1997;289-293.
66. Krebber C, Spada S, Desplancq D, Krebber A, Ge L, Plückthun A. Selectively infective phage (SIP): a mechanistic dissection of a novel method to select for protein-ligand interactions. J Mol Biol. 268:1997;619-630.
67. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 15:1997;146-156. [Published erratum appears in Nat Genet 1997, 16: 410.].